Administrative/Regulatory,
Constitutional Law,
U.S. Supreme Court
Jun. 18, 2024
Lack of standing fizzles mifepristone challenges … for the moment
The Supreme Court did not address the merits of the plaintiffs’ claims, left open the possibility of future lawsuits or policy changes, and deferred to the legislative and executive branches to amend the FDA’s authority if they deem it appropriate.
Emily Brodkin
Associate, Hooper, Lundy & Bookman, P.C.
Taryn A. Reid
Associate, Hooper, Lundy & Bookman, P.C.
Rachel Zacharias
Associate, Hooper, Lundy & Bookman, P.C.
The Supreme Court rejected a challenge to the Food and Drug Administration’s (FDA) approval of the medication abortion drug mifepristone last week, holding the Plaintiffs do not have standing to bring their case in federal court. The ruling retained the status quo for prescribing, dispensing, and accessing the drug, but left open a potential for further legal challenges and legislative action.
Background
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In